Fulvestrant,palbociclib
pfizer
['mbc', 'palbociclib', 'bcsm', 'palbo']
1st- vs 2nd-line cdk4/6i in mbc: sonia trial palbociclib used in 90%, median follow-up 37 mo primary endpoint = pfs after 2 lines of therapy:
31 vs 26.8 mo, hr 0.87 (ci 0.74-1.03), p=0.10 no difference in os or qol
consistent across subgroups gabe sonke #asco23 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.